share_log

Apollomics | 424B3: Prospectus

Apollomics | 424B3: Prospectus

Apollomics | 424B3:募資說明書
美股sec公告 ·  04/25 05:24
牛牛AI助理已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has filed a prospectus related to the primary offering of 11,026,900 Class A Ordinary Shares and a secondary offering of 52,794,176 Class A Ordinary Shares, along with 432,431 Warrants to purchase Class A Ordinary Shares. This filing is part of a registration statement pursuant to Rule 424(b)(3) with Registration No. 333-278431. The prospectus details the offer and sale of shares by Apollomics as well as the sale by certain selling securityholders named within the document. The shares and warrants are related to a business combination with Maxpro Capital Acquisition Corp., a Delaware corporation. The offerings include shares issuable upon the exercise of various warrants, including Private Warrants, Extension Warrants, Public Warrants, and Penny Warrants, with exercise prices ranging from...Show More
Apollomics Inc., a biopharmaceutical company, has filed a prospectus related to the primary offering of 11,026,900 Class A Ordinary Shares and a secondary offering of 52,794,176 Class A Ordinary Shares, along with 432,431 Warrants to purchase Class A Ordinary Shares. This filing is part of a registration statement pursuant to Rule 424(b)(3) with Registration No. 333-278431. The prospectus details the offer and sale of shares by Apollomics as well as the sale by certain selling securityholders named within the document. The shares and warrants are related to a business combination with Maxpro Capital Acquisition Corp., a Delaware corporation. The offerings include shares issuable upon the exercise of various warrants, including Private Warrants, Extension Warrants, Public Warrants, and Penny Warrants, with exercise prices ranging from $0.01 to $11.50 per share. The prospectus also outlines the potential resale of these securities by the selling securityholders through public or private transactions, at market prices or negotiated prices. The completion of the Business Combination occurred on March 29, 2023, and on the same date, Apollomics completed a sale of Class B Ordinary Shares and Series A Preferred Shares to PIPE Investors for gross proceeds of $23,650,000. On May 18, 2023, all Series A Preferred Shares were converted into Class A Ordinary Shares. The prospectus further provides information on the tax implications, legal matters, and the enforceability of civil liabilities under U.S. securities laws for investors.
生物製藥公司Apollomics Inc. 已提交了一份招股說明書,內容涉及首次發行11,026,900股A類普通股和52,794,176股A類普通股的二次發行以及432,431份購買A類普通股的認股權證。該文件是根據規則424(b)(3)提交的註冊聲明的一部分,註冊號爲333-278431。招股說明書詳細介紹了Apollomics的股票發行和出售,以及文件中提到的某些賣出證券持有人的出售。這些股票和認股權證與與特拉華州的一家公司Maxpro Capital Acquisition Corp. 的業務合併有關。此次發行包括行使各種認股權證後可發行的股票,包括私人認股權證、延期認股權證、公開認股...展開全部
生物製藥公司Apollomics Inc. 已提交了一份招股說明書,內容涉及首次發行11,026,900股A類普通股和52,794,176股A類普通股的二次發行以及432,431份購買A類普通股的認股權證。該文件是根據規則424(b)(3)提交的註冊聲明的一部分,註冊號爲333-278431。招股說明書詳細介紹了Apollomics的股票發行和出售,以及文件中提到的某些賣出證券持有人的出售。這些股票和認股權證與與特拉華州的一家公司Maxpro Capital Acquisition Corp. 的業務合併有關。此次發行包括行使各種認股權證後可發行的股票,包括私人認股權證、延期認股權證、公開認股權證和細價認股權證,行使價格從每股0.01美元到11.50美元不等。招股說明書還概述了出售證券持有人通過公開或私人交易以市場價格或協議價格轉售這些證券的可能性。業務合併於2023年3月29日完成,同日,Apollomics完成了向PIPE投資者出售B類普通股和A系列優先股的交易,總收益爲23,65萬美元。2023年5月18日,所有A系列優先股均轉換爲A類普通股。招股說明書還爲投資者提供了有關稅收影響、法律事務以及美國證券法規定的民事責任的可執行性的信息。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。